Full Press Release Details
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia.
MBX
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Key Takeaway: MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+163%
120-day peak, hindsight
Typical move
5.3%
average across 7 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
MBX 4291
Phase 1 · Obesity